FDA commissioner Robert Califf tells an Alliance for a Stronger FDA webinar that ongoing drug shortages are a huge national security risk and better i...
CDER Office of Prescription Drug Promotion cites Exeltis USA for making false or misleading claims in a social media post.
FDA plans to finalize by 9/30 its draft guidance entitled Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Sub...
Regeneron Pharmaceuticals wins FDA approval for high-dose Eylea HD (aflibercept) injection 8 mg after resolving inspection concerns at its contract ma...
FDA approves a Neurocrine Biosciences NDA for Ingrezza (valbenazine) capsules for treating adults with chorea associated with Huntingtons disease.
FDA places a partial clinical hold on Gilead Sciences studies evaluating magrolimab to treat acute myeloid leukemia.
FDA accepts for review a Geron NDA for imetelstat, a potential first-in-class telomerase inhibitor for treating transfusion-dependent anemia in patien...
Federal Register notice: FDA decides not to add ephedrine sulfate and hydroxychloroquine sulfate to its list of bulk drug substances that are acceptab...
